Conference Coverage

What Is the Best Treatment for Essential Tremor?


 

References

Nimodipine is a third-line treatment for essential tremor. Research suggests that the medication, a calcium-channel blocker, can provide improvement, but it is difficult to get insurance companies to approve it, said Dr. Hedera. Botulinum toxin A may reduce hand tremor, but the treatment is associated with dose-dependent hand weakness. Treating voice tremor with botulinum toxin A may be effective, but also may cause breathiness, hoarseness, and swallowing difficulties.

The concept of rational polypharmacy is more scientifically developed in the treatment of Parkinson’s disease, but neurologists also can apply it to essential tremor. Rational polypharmacy entails using several medications with distinct mechanisms of action to enable greater functional improvement. “I like to use monotherapy first, but I don’t shy from a combination,” said Dr. Hedera. “But there’s no data at all about any [combination’s] effectiveness, so you really have to use your clinical judgment.”

Surgical Interventions

Surgical interventions can treat essential tremor effectively, but neurologists do not have clear-cut guidelines about when to consider surgery. “It’s not a last resort,” said Dr. Hedera. If neither first-line medication successfully controls a patient’s tremor, the neurologist should strongly consider DBS treatment, he added. DBS may work best during the early part of the disease course, as it does in Parkinson’s disease.

Ventral intermediate nucleus thalamotomy and DBS produce marked or complete suppression of limb tremor in 70% to 90% of patients, according to a review published in 2009. DBS is associated with fewer adverse events than thalamotomy is, and the technique may provide long-term benefits and safety.

Although treatment can promote functional improvement and reduce anxiety, neurologists should follow their patients attentively. “It’s not like you really control tremor,” said Dr. Hedera. “You have to be 
on guard because it will come 
back at some point. We need better medications.”

Erik Greb

Pages

Recommended Reading

Pimavanserin May Relieve Parkinson’s Disease Psychosis
MDedge Neurology
CSF markers differentiate Parkinson’s, predict related dementia
MDedge Neurology
Can Nondopaminergic Drugs Help Patients With Parkinson’s Disease?
MDedge Neurology
Prion-like transmission of neurodegenerative pathology stirs concern
MDedge Neurology
MSA May Be a Prion Disorder
MDedge Neurology
The Diagnosis and Management 
of Multiple System Atrophy
MDedge Neurology
CSF Markers May Differentiate Causes of Parkinsonism and Predict Dementia
MDedge Neurology
FDA finds no evidence of cardiovascular risk in Parkinson’s drug
MDedge Neurology
Everyday Activity Is More Beneficial Than Exercise for Patients With Parkinson’s Disease
MDedge Neurology
What Is the Future of DBS for Movement Disorders?
MDedge Neurology